About this partner
Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Our lead candidate, BIO 300 is being developed for multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. Thus, reducing common treatment related side effects such as radiation induced pneumonitis, erectile dysfunction, mucositis and xerostomia. This would be a first in class drug with these dual properties. Humanetics will initiate several multi-site clinical trials for lung, prostate and head and neck cancers in 2017.
In the Know: Healthcare News for November 20, 2023
In the Know: Healthcare News for October 30, 2023
In the Know: Healthcare News for September 25, 2023
In the Know: Healthcare News for September 11, 2023